|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risk for esophageal neoplasia in B arrett’s esophagus patients with mucosal changes indefinite for dysplasia显示文摘 | Bela Horvath Prabhdeep Singh Hao Xie Prashanthi N Thota Daniela S Allende Rish K Pai Deepa T Patil Thomas P Plesec John R Goldblum Xiuli Liu | 2015 | J Gastroenterol Hepatol2015，，： | 2 |
| 2 | Robust Design in Multivariate Systems Using Genetic Algorithms 显示文摘 | Hector Allende Daniela Bravo Enrique Canessa | 2010 | Quality & Quantity2010，44，： | 1 |
| 3 | Robust Design in Multivariate System Using Genetic Algorithms显示文摘 | HECTOR ALLENDE DANIELA BRAVO ENRIQUE CANESSA | 2010 | Quality & Quantity2010，44，： | 1 |
| 4 | Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer显示文摘Background:Previous studies have demonstrated the prognostic significance of pathologic tumor response in pancreatic adenocarcinoma following neoadjuvant therapy(NAT).The aim of this study was to determine the incidence of significant pathologic response to NAT in borderline resectable pancreatic cancer(BRPC),and association of NAT regimen and other clinico-pathologic characteristics with pathologic response.Methods:Patients with BRPC who underwent NAT and pancreatic resection between January 2012 and June 2017 were included.Pathologic response was assessed on a qualitative scale based on the College of American Pathologists grading system.Demographics and baseline characteristics,oncologic treatment,pathology,and survival outcomes were compared.Results:Seventy-one patients were included for analysis.Four patients had complete pathologic responses(tumor regression score 0),12 patients had marked responses(score 1),42 had moderate responses(score 2),and 13 had minimal responses(score 3).Patients with complete or marked responses were more likely to have received neoadjuvant gemcitabine chemoradiation(62.5%,38.1%,and 23.1%of the complete/marked,moderate,and minimal response groups,respectively;P=0.04).Of the complete/marked,moderate,and minimal response groups,margins were negative in 75.0%,78.6%,and 46.2%(P=0.16);node negative disease was observed in 87.5%,54.8%,and 15.4%(P<0.01);and median overall survival was 50.0 months,31.7 months,and 23.2 months(P=0.563).Of the four patients with pathologic complete responses,three were disease-free at 66.1,41.7 and 31.4 months,and one was deceased with metastatic liver disease at 16.9 months.Conclusions:A more pronounced pathologic tumor response to NAT in BRPC is correlated with node negative disease,but was not associated with a statistically significant survival benefit in this study. | June S Peng Jane Wey Sricharan Chalikonda Daniela S Allende R Matthew Walsh Gareth Morris-Stiff | 2019 | Hepatobiliary & Pancreatic Diseases International2019，18，4： | 1 |
| 5 | Esophageal dilations in eosinophilic esophagitis: A single center experience显示文摘AIM:To diagnose the clinical and histologic features that may be associated with or predictive of the need for dilation and dilation related complications;examine the safety of dilation in patients with eosinophilic esophagitis(EoE).METHODS:The medical records of all patients diagnosed with EoE between January 2002 and July 2010were retrospectively reviewed.Esophageal biopsies were reexamined by an experienced pathologist to confirm the diagnosis(≥15 eos/hpf per current guidelines).Patients were divided into 2 groups:patients who did not receive dilation therapy and those who did.Demographics,clinical history,the use of pharmacologic therapy,endoscopic and pathology findings,and the number of biopsies and dilations carried out,if any,and their locations were recorded for each patient.The dilation group was further examined based on the interval between diagnosis and dilation,and whether or not a complication occurred.RESULTS:Sixty-one patients were identified with EoE and 22(36%)of them underwent esophageal dilations for stricture/narrowing.The peak eos/hpf was significantly higher in patients who received a dilation(P=0.04).Four(18%of pts.)minor complications occurred:deep mucosal tear 1,and small mucosal tears3.There were no cases of esophageal perforations.Higher peak eos/hpf counts were not associated with increased risk of complications.CONCLUSION:Esophageal dilation appears to be a safe procedure in EoE patients,carrying a low complication rate.No correlation was found between the peak of eosinophil count and complication rate.Complications can occur independently of the histologic features.The long-term outcome of EoE treatment,with or without dilation,needs to be determined. | Andrew Ukleja Jennifer Shiroky Amitesh Agarwal Daniela Allende | 2014 | World Journal of Gastroenterology2014，20，28： | 1 |
| 6 | 炎症性肠病患者结直肠瘤变的危险因素:一项多中心研究显示文摘背景:本研究旨在评估中国炎症性肠病(IBD)患者肠炎相关瘤变(CAN)发生的危险因素。方法:从8家医学中心收集1999-2016年间发生CAN的IBD患者。除了最初的病理评估,CAN的诊断尚需两位病理专家确认。最终筛选出29例CAN患者,并基于性别和IBD类型按1:3进行匹配,获得87例非CAN对照病例。结果:29例CAN患者中,8例(27.6%)为结直肠癌,20例(69.0%)诊断为低级别上皮内瘤变,1例(3.4%)诊断为高级别上皮内瘤变。多因素分析显示,IBD诊断年龄和IBD病程是出现CAN的独立危险因素,其OR值分别为1.09(95%CI:1.04-1.14,P<0.001)和1.14(95%CI:1.03-1.27,P=0.013)。进一步对结直肠癌与上皮内瘤变患者进行比较,结果显示,前者IBD诊断年龄更大(P=0.012),IBD病程更长(P=0.019)。结论:IBD诊断年龄更大、IBD病程更长者,发生CAN的概率增加。 | Xian-Rui Wu Xiao-Bin Zheng Yan Huang Qian Cao Hong-Jie Zhang Ying-Lei Miao Kai-Fang Zou Min Chen Fa-Ming Zhang Qiao Mei David Gonzalo Daniela Allende Pin-Jin Hu Bo Shen Xiu-Li Liu Ping Lan | 2019 | Gastroenterology Report2019，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员